← Eichor
Study identifier: NCT06354179 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

Condition: Liver Transplantation · Immunosuppression  ·  Sponsor: University Hospital, Limoges

PhasePhase 4
Planned participants162
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

World Health Organization considers non-adherence has a strong negative impact on the health of patients with chronic diseases. In transplantation, adherence to immunosuppressive drug regimens associates with late rejection and graft loss making it a critical determinant of patient outcome. The prevalence of non-adherence in transplant patients, including liver transplant patients, can be as high as 40%. Among others, life-long intake and complexity of immunosuppressive regimen make patients prone to non-adherence. For instance, non-adherence is more prevalent among patients with higher numbers of immunosuppressive drugs. One of the most commonly cited causes of non-adherence is forgetfulness and disruptions in routine, with the evening dose of twice daily regimens being the most likely to be affected6. Besides non-adherence, the constraints generated in everyday life by immunosuppression (including timely and regular drug intake) and the complexity of the immunosuppressive regimens represent a burden for the patients and are probably associated with a health-related quality of life deterioration. Therefore, long-term adherence and quality of life after liver transplantation might be improved by using a well-tolerated and easy-to-handle immunosuppressive regimen. The immunosuppressive regimen after liver transplantation is in most cases based on different combinations of tacrolimus, mycophenolate mofetil and corticosteroids. While corticosteroids are administered once daily,…

This description comes directly from the study's public registry record.

Talk to the study team

Caroline MONCHAUD, Pharm D  ·  555056140  ·  caroline.monchaud@inserm.fr

Hélène ROUSSEL  ·  helene.roussel@chu-limoges.fr

Always discuss trial participation with your own doctor first.

Locations (18)

CHU de Besançon - Hôpital Jean MinjozBesançon, FranceRecruiting
Beaujon hospital - APHPClichy, FranceRecruiting
CHU de Dijon BourgogneDijon, FranceRecruiting
CHu de GrenobleGrenoble, FranceNot Yet Recruiting
Lille university hospitalLille, FranceRecruiting
Limoges university hospitalLimoges, FranceRecruiting
Lyon university hospitalLyon, FranceRecruiting
APHPMarseille, FranceRecruiting
Montpellier university hospitalMontpellier, FranceRecruiting
Nice university hospitalNice, FranceRecruiting
Pitie Salpetriere hospital - APHPParis, FranceRecruiting
Bordeaux university hospitalPessac, FranceRecruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06354179